About 

Our Mission 

Cellengene is biopharmaceutical company dedicated to the development for CAR-T therapy targeting refractory solid tumors. Our goal is to develop 
"Off-the-Shelf" CAR-T therapy that can selectively attack cancer cells  using immune cell derived from healthy people. In order to cure pancreatic cancer, we plan to use gammadelta T cell and induced pluripotent stem cell (iPSC) platform. Furthermore, we will be enabled to cure ovarian cancer, mesothelioma and will become a global company to help many patients who are suffering from refractory cancers.
We believe next generation CAR-T therapy will give hope to many patients and lead them to have happier and healthier life.
            

History

 
2024.
▷ International patent registration approval (USA, Japan, Singapore)
2023.
▷ Patent acqusition in USA
▷ Selected as 2023 KDDF for new drug development project 
▷ Patent acquisition for Cell and Gene therapy 'CG-34 CAR-T' in Canada
▷ Domestic patent acquisition for Cell and Gene therapy 'CG-3 scFv' Mesothelin CAR-T therapy 
2022.
▷ Selected as Baby Unicorn 200 fostering project
▷ International patent registration approval (China, Australia, Japan)
▷ Follow-On Investment from Hi Investments Partners
2021.
▷ International patent application (Singapore)
▷ International patent application (U.S, Japan, Europe, Australia, Canada, China)
▷ Domestic patent acquisition
2020.
▷ Investment attraction from SJ Investment Partners
▷ Investment attraction from Soorim Venture Capital Co., Ltd.
▷ Selected as TIPS & TIPS-linked business (Start-up commercialization, overseas marketing)
▷ Attracting angel matching investment from Korea Venture Investment Co., Ltd.
2019.
▷ Acquired Kingsley Ventures Inc. VC funding
▷ Venture company Certification
▷ Moved into Seoul Biohub
▷ Small business Certification
▷ Established enterprise affiliated research institute
▷ Established Cellengene Inc.
▷ Biohealth Innovation Start-up Members (Moved into Yonsei Bongrae Building)

 CAR-T Therapy

CAR-T therapy is one of the immunotherapy, including genetically modified T cell expressing unique receptor "Chimeric Antigenic Receptor" .  This unique receptor binds to certain protein on patient's cancer cells and selectively attack them.  In current situation, FDA approval were granted to 6 types of treatment targeting hematological malignancies, including “Kymriah” from Novartis and “Yescarta & Tecartus” from Gilead, "Breyanzi & Abecma" from BMS, "Carvykti" from Johnson & Johnson.  There are many ongoing researches, developments and clinical stages on CAR-T therapy but no succeed case appears yet. 

 

In general, there are two ways to manufacture CAR-T therapy.  Autologous CAR-T  is personalized therapy that does not incur GvHD.  Because it is  derived from patient's own cell and reinjected to the patient. However, manufacturing process takes at least 3 weeks and costs are very expensive. Allogenic CAR-T is universal therapy that require genetically engineering process and mass production is available. Manufacturing process takes approximately 1 week and costs are lower than autologous CAR-T production. Therefore, immediate injection is available for hundreds of patients. 

CAR-T Platform

 

 

 

Genome Editing Technology

Preventing GvHD and overcoming tumor microenvironment(TME) are key factors to develop allogenic CAR-T therapy. In order to overcome these certain problems, TCR is knockout using CRISPER/CAS9 gene editing technology and immune check receptor, PD-1, is  knockdown to induce T cell activation and attack cancer cell continuously. 

News

Notice 

no category title name date view

Career 

E.  contact@cellengene.com
T.  (+82) 2-966-2676

INQUIRY FOR JOB POSITIONS

SEND MESSAGE

Contact

Headquarter
5th Floor, Pangyo Techno Valley Startup Campus 20, Pangyo-ro 289 beon-gil, Bundang-gu, Seongnam-si,                         
Gyeonggido, Korea, 13488   
R&D Center
Global Cooperation Building Rm 302, Seoul Bio Hub
117-3 Hoegi-ro, Dongdaemun-gu, Seoul,
Republic of Korea, 02455
TEL
(+82) 2-966-2676
FAX
(+82) 2-6442-5756
E-mail
contact@cellengene.com
SEND MESSAGE